| [1] | Castillo DR, Park D, Mehta A, et al. Outcomes of the pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review[J]. Hematol Rep, 2022, 14(1): 45-53. doi: 10.3390/hematolrep14010008
 | 
																													
																						| [2] | Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J]. Leukemia, 2008, 22(1): 14-22. pmid: 17882280
 | 
																													
																						| [3] | Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. doi: 10.1182/blood-2016-03-643544
																																					pmid: 27069254
 | 
																													
																						| [4] | Szakács Z, Hegyi PJ, Farkas N, et al. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a systematic review[J]. PLoS One, 2020, 15(12): e0243045. | 
																													
																						| [5] | Dou X, Qin Y, Huang X, et al. Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy[J]. Oncologist, 2019, 24(11): e1141-e1147. | 
																													
																						| [6] | Berman E. Pregnancy in patients with chronic myeloid leukemia[J]. J Natl Compr Canc Netw, 2018, 16(5S): 660-662. doi: 10.6004/jnccn.2018.0035
 | 
																													
																						| [7] | Abruzzese E, Mauro M, Apperley J, et al. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations[J]. Ther Adv Hematol, 2020, 11: 2040620720966120. | 
																													
																						| [8] | Hehlmann R. The new ELN recommendations for treating CML[J]. J Clin Med, 2020, 9(11): 3671. | 
																													
																						| [9] | Barzilai M, Avivi I, Amit O. Hematological malignancies during pregnancy[J]. Mol Clin Oncol, 2019, 10(1): 3-9. doi: 10.3892/mco.2018.1759
																																					pmid: 30655971
 | 
																													
																						| [10] | Rohilla M, Rai R, Yanamandra U, et al. Obstetric complications and management in chronic myeloid leukemia[J]. Indian J Hematol Blood Transfus, 2016, 32(1): 62-66. | 
																													
																						| [11] | Balsat M, Etienne M, Elhamri M, et al. Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era[J]. Eur J Haematol, 2018, 101(6): 774-780. doi: 10.1111/ejh.13167
																																					pmid: 30179268
 | 
																													
																						| [12] | Abu-Tineh M, Kassem N, Abdulla MA, et al. Outcome of pregnancy in the era of PEGylated interferon-α2a in females with chronic myeloid leukemia: an experience from Qatar[J]. Case Rep Oncol, 2020, 13(1): 291-294. doi: 10.1159/000506590
																																					pmid: 32308593
 | 
																													
																						| [13] | Madabhavi I, Sarkar M, Modi M, et al. Pregnancy outcomes in chronic myeloid leukemia: a single center experience[J]. J Glob Oncol, 2019, 5: 1-11. doi: 10.1200/JGO.18.00211
																																					pmid: 31584851
 | 
																													
																						| [14] | Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy[J]. Anticancer Res, 2015, 35(1): 1-11. pmid: 25550528
 | 
																													
																						| [15] | Ono T. Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase?[J]. Cancers (Basel), 2021, 13(20): 5116. | 
																													
																						| [16] | Rambhatla A, Strug MR, De Paredes JG, et al. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review[J]. J Assist Reprod Genet, 2021, 38(8): 1897-1908. doi: 10.1007/s10815-021-02181-6
 | 
																													
																						| [17] | Hochhaus A, Baccarani M, Silver RT, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia[J]. Leukemia, 2020, 34(4): 966-984. doi: 10.1038/s41375-020-0776-2
																																					pmid: 32127639
 | 
																													
																						| [18] | Samal R, Ghose S. Chronic myeloid leukaemia in pregnancy: call for guidelines[J]. J Obstet Gynaecol, 2019, 39(4): 582-583. doi: 10.1080/01443615.2018.1534815
																																					pmid: 30744447
 |